News summary

Atlas Bio steps out of stealth with $12.5m funding

Source: Startupticker.ch • Published: 27 Oct 2026, 00:00

Summarized by Masters of Longevity from Startupticker.ch.

Swiss-founded biotech launched an AI model that simulates human drug effects.

Atlas Bio steps out of stealth with $12.5m funding
Key Takeaways
  • Atlas Bio has an AI model trained on human RNA.
  • Their platform was reported to predict patient responses before Phase II.
  • Their simulations have already replaced animal studies for one program.
Read the full article at Startupticker.ch ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickCan Doctors Be Trained for the Longevity Era?A new global survey suggests that healthy longevity medicine education can change how physicians think and talk about ageing. But the evidence also highlights how much work remains before a rapidly growing field becomes routine clinical care.